SRD5A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bexlosteride (SCHEMBL225678)	1.00	20/20
Bexlosteride (SCHEMBL225679)	1.00	20/20
Dutasteride (SCHEMBL5903)	1.00	19/20
SCHEMBL916784	1.00	18/20
SCHEMBL916785	1.00	18/20
SCHEMBL916924	1.00	18/20
SCHEMBL916926	1.00	18/20
SCHEMBL917612	1.00	18/20
SCHEMBL918267	0.86	18/20
SCHEMBL918268	0.86	18/20
SCHEMBL916370	0.84	18/20
SCHEMBL916372	0.84	18/20
SCHEMBL917238	0.84	18/20
SCHEMBL917240	0.84	18/20
SCHEMBL917560	0.59	18/20
Finasteride (SCHEMBL298276)	0.56	18/20
SCHEMBL916345	1.00	17/20
SCHEMBL916346	1.00	17/20
SCHEMBL916799	1.00	17/20
SCHEMBL917213	1.00	17/20

Clinical trials — most relevant to SRD5A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment	PHASE4	RECRUITING
The Role of 5-alpha Reductase in Mediating Testosterone Actions	PHASE4	COMPLETED
Comparisons of Different Forms of Glucocorticoid on the Recovery of Reproductive Function in Patients With 21α-hydroxylase Deficiency	PHASE4	UNKNOWN
Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents	PHASE3	WITHDRAWN
The Effect of 5-Alpha Reductase on Testosterone in Men	PHASE3	UNKNOWN
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study	PHASE3	UNKNOWN
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]	PHASE1/PHASE2	COMPLETED
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia	PHASE2	RECRUITING
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	PHASE2	COMPLETED
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy	PHASE2	NOT_YET_RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
Mutation Analysis of 17βhydroxysteroid Dehydrogenase 3 Deficiency	nan	UNKNOWN
Determining the Long-Term Effects of Prenatal Dexamethasone Treatment in Children With 21-Hydroxylase Deficiency and Their Mothers	nan	UNKNOWN
Final Height in Patients With CAH	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Effect of Surgical or Conservative Approach in Patients With Adrenal Incidentalomas	nan	UNKNOWN
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency	nan	COMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Early Mental Response - The EMRE Study	nan	RECRUITING
Exercise Capacity, Physical Fitness, and Physical Activity Levels in Children With CAH	nan	COMPLETED
Androgen Metabolism and Reproductive Outcome	nan	COMPLETED
Mutation Analysis of 17α-Hydroxylase	nan	UNKNOWN
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity	nan	RECRUITING
FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study	nan	RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SRD5A1 binder may also engage these)

Protein	Name	Similarity
Q28891	—	1.000	Q28891 →
A5PJS2	—	0.992	A5PJS2 →
Q68FF9	—	0.987	Q68FF9 →
P24008	—	0.987	P24008 →
P31214	—	0.980	P31214 →
Q99N99	—	0.980	Q99N99 →
Q28892	—	0.976	Q28892 →
O18765	—	0.972	O18765 →
SRD5A2	3-oxo-5-alpha-steroid 4-dehydrogenase 2	0.966	landscape →
I1HTF7	—	0.964	I1HTF7 →
Q9CAH5	—	0.963	Q9CAH5 →
Q7XUH5	—	0.963	Q7XUH5 →
A2XWN6	—	0.963	A2XWN6 →
Q9SI62	—	0.959	Q9SI62 →
C7T2J9	—	0.959	C7T2J9 →
Q9WVM4	—	0.957	Q9WVM4 →
Q7F0Q2	—	0.956	Q7F0Q2 →
B8B6G5	—	0.955	B8B6G5 →
Q9H8P0	—	0.955	Q9H8P0 →
Q9EQK7	—	0.955	Q9EQK7 →
Q0P4J9	—	0.954	Q0P4J9 →
Q7XSR9	—	0.952	Q7XSR9 →
Q5RIU9	—	0.952	Q5RIU9 →
ICMT	Protein-S-isoprenylcysteine O-methyltransferase	0.952	landscape →
B7F9G7	—	0.951	B7F9G7 →
Q7ZXH1	—	0.951	Q7ZXH1 →
O88455	—	0.950	O88455 →
Q9Z2Z8	—	0.950	Q9Z2Z8 →
Q9WUP4	—	0.950	Q9WUP4 →
Q71KT5	—	0.950	Q71KT5 →